Seek Labs Welcomes Esteemed Diagnostics Industry Innovator and Executive, Dr. Randy Rasmussen, PhD, to Board of Directors

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, is pleased to announce the appointment of Randy Rasmussen, PhD, to its Board of Directors, effective March 27, 2024. Dr. Rasmussen brings over three decades of experience in molecular diagnostic development and management to Seek Labs that will significantly contribute to the company’s strategic vision for diagnostic technologies for the point of care.

Having amassed a remarkable track record of advancements in molecular diagnostic technologies throughout his career, Dr. Rasmussen is a highly regarded figure in the field of molecular diagnostics. His extensive knowledge and background in molecular biology and Syndromic testing, coupled with a passion for patient-focused diagnostic innovation, positions Dr. Rasmussen as a valuable addition to Seek Labs as the company progresses toward product development and commercialization.

"We are delighted to welcome Randy Rasmussen to Seek Labs’ Board of Directors," said Jared Bauer, CEO. "His unparalleled expertise in molecular diagnostic development will undoubtedly enrich our board's collective knowledge and drive our commitment to innovation in the field. We look forward to leveraging Randy's insights as we continue to advance our mission of moving molecular diagnostics to the point of care."

Randy Rasmussen co-founded BioFire Diagnostics (previously Idaho Technology) in 1991. Dr. Rasmussen, who went on to hold positions as President, COO, and CEO, led BioFire through countless milestones, including growing the company to over 3,000 employees, developing biothreat surveillance technologies for the US military, and inventing the field of Syndromic testing for easy diagnosis of infectious disease syndromes. Dr. Rasmussen also led BioFire through a successful $500M sale to BioMérieux and strategically supported a dual IPO/acquisition path led by JP Morgan in 2020.

Dr. Rasmussen expressed his excitement to join Seek Labs’ Board and contribute to the company’s success: “Seek Labs’ commitment to molecular diagnostic innovation aligns with my own passion for diagnostic innovation and improving healthcare outcomes. I am eager to collaborate with the board and management team to chart a course for continued growth and impact in the field of diagnostics."

Dr. Rasmussen earned a BSc in Biochemistry from Utah State University and went on to earn a PhD in Molecular Biology from the University of Utah. Dr. Rasmussen has authored or co-authored over 20 publications and has developed several patented technologies. Dr. Rasmussen currently serves as Chairman of the Board for BioUtah and as a Board Member for Quansys Biosciences.

About Seek Labs

Seek Labs is a company united by a vision to advance scientific discovery and universal solutions. Seek Labs strives to innovate healthcare solutions that bridge gaps between patients, providers, and treatments. Seek Labs is united by the passion of our founders and their shared beliefs that healthcare solutions should empower individuals and serve their specific needs. Today—after years of experimentation, failure, and breakthrough— Seek Labs is developing new solutions for point-of-care diagnostics and CRISPR-based pharmaceutical technologies that have the potential to revolutionize the detection and treatment of diseases.

Seek Labs is headquartered in Salt Lake City, Utah. Seek Labs is a proud member of the BioHive, a collective representing the life science and healthcare innovation ecosystem in Utah. BioHive is dedicated to all the ways our work can positively impact the lives of our community, our teams, and patients.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240329498878/en/